Novartis has entered into an agreement to acquire Regulus Therapeutics, a clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus’ lead asset, farabursen, is a next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). “With limited treatment options currently available for patients suffering from ADPKD,… Read More
The Nobel Assembly at Karolinska Institutet has awarded the 2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. Victor Ambros is Silverman Professor of Natural Science at the University… Read More
Australian researchers have analysed how an antidiabetic treatment could help control the growth of tumours, potentially paving the way for the design of better cancer treatments. The new study investigated what happens when metformin, a type 2 diabetes medication, is used to treat colorectal cancer cells,… Read More
